showed a trendp = 0.1
Patients with MMR-deficient tumors showed a trend towards a better 3-year overall survival (96.3% vs . 83.5%; p = 0.1, log rank).
Patients with MMR-deficient tumors showed a trend towards a better 3-year overall survival (96.3% vs . 83.5%; p = 0.1, log rank).